According to the latest developments ...

According to the latest developments to optimize therapy using dose ratio (dose of moclobemide in relation to amitriptyline) not less than 3:1. Aids may be small doses of benzodiazepines (Nitrazepam, Lorazepam, relanium, phenazepam) and / or neuroleptics (sonapaks, hlorprotiksen, teralen, neuleptil) exhibit therapeutic synergism. Significant age restrictions for use of moclobemide is currently unknown, and drug use in young, mature, and old age. Good tolerability of moclobemide patients can include it in a therapeutic regimen in the acute period of depression (from 4 to 12 weeks) and at a subsequent period of stabilization (from 4 months to 1 year or more), including supervision in the outpatient setting. Use of standard daily doses (300750 mg), leading to therapeutic effect in depression is mild to moderate severity, usually not accompanied by any hematological or biochemical changes, as well as complications that threaten life and indicative of drug toxicity. Not observed, and such conventional therapy during the traditional tricyclic antidepressants reactions as tachycardia, dry mouth, urogenital disorders, dyspeptic disorders, cognitive dysfunction, confirming the lack of anticholinergic and cardiovascular side effects. Side effects of treatment with moclobemide compliance with therapeutic recommendations are rare (headache, nausea, allergic reactions), expressed little and are transient in nature. In connection with the possibility of an undesirable effect of the drug combination therapy with moclobemide and tricyclic antidepressants or drugs of the selective serotonin reuptake inhibitors (fluoxetine, sertraline, fluvoxamine, paroxetine) is impractical, which corresponds to a tendency to limit the use of complex combinations of psychotropic drugs in general medicine. Absolutely do not recommend a combination of moclobemide with clomipramine (anafranilom) due to violations of test security (giperserotoninergichesky death syndrome), as well as some somatotropic drugs (cimetidine, etc.). Direct STH moclobemide affect the least studied. However, it is known that the appointment of the drug to patients suffering from both depression and hypertension arterilnoy, it is possible to achieve a double effect: an antidepressant and antihypertensive. Hepatotoxic complications that caused the rejection of the application of the first representatives of MAOIs, moclobemide treatment is rare. According to the results of several studies moclobemide does not aggravate typical depression of sexual dysfunction. The presence of somatic pathology is not a contraindication to therapy moclobemide, restrictions apply only to the standard requirements for all antidepressants, such as pregnancy and / or the presence of severe physical illness.